Paula Lana de Miranda Drummond

Dr. Paula Lana de Miranda Drummond

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
JMJessica Soares Malta
Jessica Soares Malta
LSLívia Pena Silveira
Lívia Pena Silveira
PDPaula Lana de Miranda Drummond
Paula Lana de Miranda Drummond
NCNaiane Lima Costa
Naiane Lima Costa
RSRoberta Márcia Marques dos Santos
Roberta Márcia Marques dos Santos
CPCristiane Aparecida Menezes de Pádua
Cristiane Aparecida Menezes de Pádua
Multiple myeloma (MM) is a rare but treatable hematological cancer, which makes Health-Related Quality of Life (HRQoL) an important patient-report outcome measure in clinical studies. The Quality o...

1 August 2024 in Current Drug Safety
Verified
Journal Article
Closed access
PDF file
PDPaula Lana de Miranda Drummond
Paula Lana de Miranda Drummond
RSRoberta Márcia Marques dos Santos
Roberta Márcia Marques dos Santos
LSLívia Pena Silveira
Lívia Pena Silveira
JMJessica Soares Malta
Jessica Soares Malta
ARAdriano Max Moreira Reis
Adriano Max Moreira Reis
CPCristiane Aparecida Menezes de Pádua
Cristiane Aparecida Menezes de Pádua
Background: Survival in multiple myeloma (MM) has improved in the past years with the introduction of immunomodulators and proteasome inhibitors. However, chemotherapyinduced peripheral neuropathy (CIPN) is associated with both drug classes affecting Health- Related Quality of Life (HRQoL) and activities of daily living (ADL). Objective: We evaluated CIPN in MM patients to identify associated factors and impacts on HRQoL and ADL. Methods: This is a cross-sectional study with Brazilian patients from public and private health services. Patients were interviewed using validated tools to measure CIPN and HRQoL, along with sociodemographic and clinical questions. Logistic regression was used to assess the association of CIPN with sociodemographic, clinical, and HRQoL variables. Results: In total, 217 patients were eligible for the study. The median age was 67, 50.9% were women, 51.6% had low income, 47.5% had low education, and 55.3% attended private health services. The chemotherapy regimen most used was the combination of cyclophosphamide, thalidomide, and dexamethasone (17.5%) among the 24 types of regimens found. Most patients (90.3%) had at least one CIPN symptom: 62.7% were severe, and 51.62% were extremely bothered ADL. Numbness was the most common symptom (40.6%). CIPN was independently associated with education, hospitalization, chemotherapy, side effects, disease symptoms, and global health status in HRQoL. Conclusion: MM patients showed a high frequency of CIPN, which affected ADL and impaired HRQoL. Early and accurate detection of CIPN and dose management in patients with thalidomide and bortezomib-based regimens should be performed to provide better treatment outcomes and avoid permanent disabilities.

1 January 2019 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
PDPaula Lana de Miranda Drummond
Paula Lana de Miranda Drummond
RSRoberta Márcia Marques dos Santos
Roberta Márcia Marques dos Santos
GCGabriela Oliveira Carvalho
Gabriela Oliveira Carvalho
CPCristiane Aparecida Menezes de Pádua
Cristiane Aparecida Menezes de Pádua
Keywords: Thalidomide; Leprosy; Adverse events; Pharmacovigilance; Drug safety

6 June 2023 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
MLMariana Sampaio Rodrigues de Lima
Mariana Sampaio Rodrigues de Lima
CPCristiane Aparecida Menezes de Pádua
Cristiane Aparecida Menezes de Pádua
PDPaula Lana de Miranda Drummond
Paula Lana de Miranda Drummond
LSLívia Pena Silveira
Lívia Pena Silveira
JMJessica Soares Malta
Jessica Soares Malta
ARAdriano Max Moreira Reis
Adriano Max Moreira Reis

1 August 2023 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
TMTaisa R L Machado
Taisa R L Machado
CPCristiane A M de Pádua
Cristiane A M de Pádua
PDPaula Lana de Miranda Drummond
Paula Lana de Miranda Drummond
LSLívia P Silveira
Lívia P Silveira
JMJéssica S Malta
Jéssica S Malta
ARAdriano Max Moreira Reis
Adriano Max Moreira Reis
Introduction: Elderly with cancer often have multimorbidity, which determines a higher risk of polypharmacy. This is related to negative clinical results such as adverse drug reaction and emergence service visits. Furthermore, polypharmacy increases the risk of using potentially inappropriate medications. Objective: To evaluate the use of potentially inappropriate medication in elderly with multiple myeloma and associated factors. Methods: The study was conducted with older adults with multiple myeloma treated at outpatient oncology and hematology services in a southeastern Brazilian capital. Potentially inappropriate medications were classified using the American Geriatric Society/Beers 2019 Criteria. Variables were described using frequency and proportions, performing multiple logistic regression to identify factors associated with the use of potentially inappropriate medications. Results: One hundred fifty-three older adults with multiple myeloma were included, with a median age of 70.9 years. The median number of medications was 8, and 63% of patients used polypharmacy. More than half (54%) of the patients used potentially inappropriate medications, and proton pump inhibitors (46%) and benzodiazepines (8%) were the most employed therapeutic classes. Older adults who used potentially inappropriate medications differed from those who did not use them in the following characteristics: income up to three minimum wages, higher schooling level, private service, multimorbidity, hypertension, cardiovascular disease, chronic kidney disease, depression, adverse event, and polypharmacy. Higher schooling levels and polypharmacy were independently associated with the use of potentially inappropriate medications in the multivariate analysis. Conclusion: Potentially inappropriate medication use was high in patients with multiple myeloma studied. The use of polypharmacy and higher schooling levels were independently and positively associated with the use of potentially inappropriate medications.

18 June 2025 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDPaula Lana de Miranda Drummond
Paula Lana de Miranda Drummond
CSCristine de Araújo Silva
Cristine de Araújo Silva
JSJúlia Estevão de Souza
Júlia Estevão de Souza
BMBárbara Alice Rocha Magno
Bárbara Alice Rocha Magno
GBGiovanna Marchetti Battaglia
Giovanna Marchetti Battaglia
BPBruno Gonçalves Pereira
Bruno Gonçalves Pereira
Objective: The aim of this overview was to summarize evidence of the efficacy and safety of thalidomide in the treatment of oncology-related diseases approved in Brazil, and to assess the quality of the available data. Methods: A literature search was performed in the Cochrane Library, PubMed, Embase, Lilacs, and SciELO databases. Studies must contain evidence of efficacy and/or safety of thalidomide use for multiple myeloma – MM, graft-versus-host disease – GVHD, and myelodysplastic syndrome - MDS. The extracted information were: authors, year, literature search, studies design, target population, studies sample, comparisons and thalidomide dose, funding, outcomes, results / pooled effect, heterogeneity, conclusion. Results: This overview showed the available data about efficacy and safety of thalidomide used in the treatment of oncology-related approved indications in Brazil. It also classified the methodological quality of studies according to Amstar 2 tool. Despite of the poor quality of the articles found, they supported the efficacy of thalidomide in MM treatment. The main adverse events reported were peripheral neuropathy, infections, hematological, thromboembolic, and gastrointestinal events. Evidence supported that the more drugs combined, the greater the efficacy, but there is also a greater risk of toxicity. For the indications of GVHD and MDS no systematic reviews and/or meta-analyses that met the inclusion criteria were found. Conclusions: The overview confirmed thalidomide's efficacy on MM. It is important to monitor and manage the occurrence of thalidomide-related adverse events. Strict control over its use must always be reinforced to maintain its safe use.